EUVIMEDEUVIMED entdecken
Open Access

Exposure proximal immune correlates analysis

Ying Huang iD, Dean Follmann

Biostatistics · 2025

DOI: 10.1093/biostatistics/kxae031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biostatistics, 2025. Verfasst von Ying Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics, Bioinformatics and Epidemiology Program, Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Se…. Hauptthemen laut MEDLINE: Vaccine Efficacy, COVID-19 Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune response decays over time, and vaccine-induced protection often wanes. Understanding how vaccine efficacy changes over time is critical to guiding the development and application of vaccines in preventing infectious diseases. The objective of this article is to develop statistical methods that assess the effect of decaying immune responses on the risk of disease and on vaccine efficacy, within the context of Cox regression with sparse sampling of immune responses, in a baseline-naive population. We aim to further disentangle the various aspects of the time-varying vaccine effect, whether direct on disease or mediated through immune responses. Based on time-to-event data from a vaccine efficacy trial and sparse sampling of longitudinal immune responses, we propose a weighted estimated induced likelihood approach that models the longitudinal immune response trajectory and the time to event separately. This approach assesses the effects of the decaying immune response, the peak immune response, and/or the waning vaccine effect on the risk of disease. The proposed method is applicable not only to standard randomized trial designs but also to augmented vaccine trial designs that re-vaccinate uninfected placebo recipients at the end of the standard trial period. We conducted simulation studies to evaluate the performance of our method and applied the method to analyze immune correlates from a phase III SARS-CoV-2 vaccine trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccine EfficacyCOVID-19 VaccinesHumansCOVID-19Models, StatisticalComputer SimulationRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

exposure-proximal correlatesinduced partial likelihoodtwo-phase samplingvaccine trial

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Biostatistics, Bioinformatics and Epidemiology Program, Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA, 98109.
  • Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, 5601, MA.

ORCID-Profile: Ying Huang

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • NIH

Zitieren

APA

Huang, Y., & Follmann, D. (2025). Exposure proximal immune correlates analysis. Biostatistics. https://doi.org/10.1093/biostatistics/kxae031

Vancouver

Huang Y, Follmann D. Exposure proximal immune correlates analysis. Biostatistics. 2025. doi:10.1093/biostatistics/kxae031

BibTeX
@article{Huang2025,
  author = {Huang, Ying and Follmann, Dean},
  title = {Exposure proximal immune correlates analysis},
  journal = {Biostatistics},
  year = {2025},
  doi = {10.1093/biostatistics/kxae031}
}
Kostenlos starten →